Skip to Content
Center for International Blood and Marrow Transplant Research

CIBMTR at 2026 ASH Annual Meeting

Main Content

CIBMTR will have an outstanding presence at the 2026 American Society of Hematology (ASH) Annual Meeting, with 27 accepted abstracts: 14 oral presentations and 13 posters. These abstracts represent the work of 298 authors from 85 institutions. Of the 26 different presenting authors, 17 are junior including 2 fellows and 2 research scientists/post-docs. Together, these presentations showcase the breadth and impact of CIBMTR research and its potential to advance care across hematology and cellular therapy.

Beyond the numbers, this year’s presentations tell a broader story about CIBMTR’s role in generating evidence that can expand access to treatment, improve the safety and precision of cell therapy, and answer questions that require large-scale clinical trials, registry data, and collaborative science.

Expanding donor options

Several studies address one of the field’s most important challenges: helping more patients proceed to transplant when a fully matched donor does not exist.

Results from the ACCESS trial continue to build evidence supporting mismatched unrelated donor transplantation with post-transplant cyclophosphamide (PTCy). Two-year findings show outcomes that were broadly comparable with those observed in a major matched-donor trial, despite ACCESS enrolling patients receiving mismatched unrelated donor transplants and a larger proportion of patients that were ethnically diverse. Another ACCESS analysis found that patients had similar longer-term quality-of-life trajectories compared with matched-donor and real-world cohorts, even when early physical recovery was slower.

A related CIBMTR registry or observational analysis examined whether the specific HLA locus involved in a 7/8 donor mismatch affected outcomes. The results found no meaningful differences by mismatched locus, suggesting that clinicians may be able to place greater emphasis on factors such as younger donor age when choosing among available mismatched unrelated donors.

Why it matters: Together, these findings support a less restrictive approach to donor selection. This could allow more patients, including those less likely to identify a fully matched donor, many of whom are racially and ethnically diverse, to move forward with transplantation using the best available donor.

Making transplantation safer and more precise

Expanding access is only part of the goal. Other CIBMTR studies are asking how treatment can be refined to reduce complications without sacrificing effectiveness.

The OPTIMIZE trial is testing whether lower doses of PTCy can preserve protection against graft-versus-host disease while reducing toxicity and infection burden. Initial reduced-dose results showed favorable infection-free survival, approximately 89% one-year overall survival and low non-relapse mortality. Results from a separate safety cohort also support continued study of intermediate-dose PTCy in patients receiving highly mismatched unrelated donor transplants.

Another analysis found that high exposure to fludarabine was independently associated with greater non-relapse mortality and worse survival. These results support prospective evaluation of personalized, model-informed dosing rather than relying exclusively on conventional dosing approaches.

Two analyses from the GVHD Working Committee explore how evolving GVHD prevention strategies, particularly with PTCy, impact patterns of acute GVHD post-HCT and whether use of mycophenolate mofetil (MMF) enhances GVHD prevention.

Why it matters: These studies move beyond asking whether PTCy-based GVHD prophylaxis works in the HLA matched and mismatched settings. They ask how treatment can be refined for individual patients to reduce infections, toxicity and other complications while maintaining transplant outcomes.

Seeing residual AML more clearly

Four oral presentations from the MEASURE program focus on improving measurable residual disease, or MRD, assessment in acute myeloid leukemia (AML).

MEASURE prospectively validated a whole-genome-informed approach to MRD testing that strongly identified patients at increased risk of relapse. Additional studies evaluated complementary approaches, including a tumor-agnostic blood-based methylation assay and personalized DNA-based testing for KMT2A-altered AML. Both approaches identified residual disease or elevated risk in patients who could be missed by conventional flow cytometry.

A fourth study examined patients treated with hypomethylating agents and venetoclax before transplant. Patients who achieved MRD-negative remission had a low risk of relapse and outcomes comparable with MRD-negative patients treated with intensive chemotherapy, supporting the value of MRD for risk assessment across different treatment strategies.

Why it matters: More sensitive and broadly applicable MRD testing could help clinicians better understand a patient’s risk before transplant and eventually support more individualized treatment and monitoring decisions.

Understanding CAR T in the real world

As CAR T-cell therapy reaches more patients, important questions surface like: How can clinicians better anticipate toxicity? What happens to patients over longer periods of follow-up? And what safety concerns emerge as these therapies are used more broadly?

Four CIBMTR studies at ASH address different pieces of that picture, using registry data to examine prediction of early CAR T-cell toxicity, subsequent primary malignancies after CAR T-cell therapy, and longer-term real-world safety and effectiveness of commercial CAR T-cell therapies - Tisagenlecleucel and lisocabtagene maraleucel.

Why it matters: Longitudinal registry research complements clinical trials by allowing researchers to study patients treated in real-world settings and follow outcomes over time. Together, these studies demonstrate how CIBMTR data can help build a more complete picture of CAR T-cell therapy as its use continues to evolve.

Building evidence where evidence is difficult to generate

Some important questions in hematology are difficult to answer because the conditions being studied are rare or data for specific patient populations are limited. In these settings, bringing together data across institutions in a registry setting, including collaboration across registries, can make it possible.

At ASH, seven related CIBMTR studies examine the role of hematopoietic cell transplantation across rare peripheral T-cell lymphoma subtypes. Another study, conducted jointly by CIBMTR and the European Society for Blood and Marrow Transplantation (EBMT) examines HCT outcomes among patients with Down syndrome-associated AML in the modern era.

Why it matters: These studies demonstrate how CIBMTR’s scale and collaborative research network can help answer important clinical questions that would be difficult for any individual center to study, particularly when available data are limited.

And there’s more

CIBMTR’s presence at ASH extends beyond these featured research themes. Additional presentations examine conditioning approaches for haploidentical HCT, health outcomes among socially vulnerable pediatric transplant recipients, and biomarkers associated with GVHD and mortality. Together, they further illustrate the breadth of questions CIBMTR research is addressing across transplantation and cellular therapy.

A shared accomplishment

This year’s ASH presence reflects the combined contributions of investigators, scientific, statistical, and operational teams, clinical research staff, working committees, participating centers, patients and partners across CIBMTR.

Congratulations to everyone whose work contributed to this outstanding showing and to the presenters who will represent CIBMTR at ASH 2026.

Title Status Date/Time/Session Presenter
SATURDAY, DECEMBER 12
CIBMTR comparison of reduced intensity conditioning regimens for haploidentical hematopoietic cell transplant with post-transplant cyclophosphamide in myeloid malignancies Oral December 12
2:00 PM - 2:30 PM
Presentation: 2:45 PM
Session: 721
Hany Elmariah
Incidence, characteristics, and risk factors for developing subsequent primary malignancies in chimeric antigen receptor T-cell therapy recipients and its impact on survival: A CIBMTR analysis Oral December 12
2:00 PM - 3:30 PM
Presentation: 2:45 PM
Session: 906
Vivian Irizarry Gatell
Tumor-agnostic plasma cell-free DNA methylation profiling for measurable residual disease in patients with acute myeloid leukemia Oral December 12
2:00 PM - 3:30 PM
Presentation: 3:00 PM
Session: 803
Gege Gui
External validation of model-informed fludarabine exposure as a predictor of non-relapse mortality after PTCy-based allogeneic hematopoietic cell transplantation Oral December 12
4:00 PM - 5:30 PM
Presentation: 4:30 PM
Session: 721
Mohammed Alhomoud
Outcomes of hematopoietic cell transplantation in subcutaneous panniculitis-like T-cell lymphoma: A CIBMTR analysis Oral December 12
4:00 PM - 5:30 PM
Presentation: 4:30 PM
Session: 732
Daniel Reef
Improved outcomes of hematopoietic cell transplantation in down syndrome acute myeloid leukemia (DS-AML) in the modern era: A combined CIBMTR/EBMT analysis Oral December 12
4:00 PM - 5:30 PM
Presentation: 4:45 PM
Session: 732
Lauren Appell
Prospective multicenter validation of whole genome-informed acute myeloid leukemia measurable residual disease testing: The MEASURE study Oral December 12
4:00 PM - 5:30 PM
Presentation: 5:15 PM
Session: 619
Chris Hourigan
Real-world long-term safety and efficacy of tisagenlecleucel in relapsed or refractory follicular lymphoma from the CIBMTR registry Poster December 12
5:30 PM - 7:30 PM
Session: 623
Daniel Landsburg
Angioimmunoblastic-type (AITL) versus non-AITL nodal T-follicular helper cell lymphoma: A CIBMTR analysis of autologous hematopoietic cell transplantation outcomes Poster December 12
5:30 PM - 7:30 PM
Session: 625 
Ibrahim Muhsen
Predicting early CAR T-cell toxicity in DLBCL using machine learning: An internally validated CIBMTR registry study Poster December 12
5:30 PM - 7:30 PM
Session: 628
Shatha Farhan
Longitudinal profiling of cytokines and chemokines identifies novel biomarkers of graft-versus-host disease and mortality after allogeneic hematopoietic cell transplantation Poster December 12
5:30 PM - 7:30 PM
Session: 722
Michael Martens
Outcomes of patients with Extranodal Natural Killer/T- cell lymphomas (ENKTCL) undergoing consolidative hematopoietic cell transplantation (HCT): A CIBMTR Analysis Poster December 12
5:30 PM - 7:30 PM
Session: 732  
Amrita Desai
SUNDAY, DECEMBER 13  
HLA mismatched locus impact on outcomes in mismatched unrelated donor hematopoietic cell transplantation using post-transplant cyclophosphamide GVHD prophylaxis for acute leukemia or myelodysplastic syndrome: A CIBMTR retrospective analysis Oral December 13
9:30 AM - 11: 00 AM
Presentation: 9:30 AM
Session: 722
Stephen Spellman
Post-transplant cyclophosphamide is associated with differences in acute gvhd organ distribution and severity after HLA-matched unrelated donor hematopoietic cell transplantation compared with calcineurin inhibitor- based gvhd prophylaxis Oral December 13
9:30 AM - 11: 00 AM
Presentation: 10:00 AM
Session: 722
Rima Saliba
Personalized DNA-based multiplex ddpcr for MRD detection in patients with KMT2A-altered AML Oral December 13
9:30 AM - 11:00 AM
Presentation: 10:30 AM
Session: 723
Rasha Al-Ali
Intermediate-dose post-transplantation cyclophosphamide for highly HLA-mismatched unrelated donor PBSC transplantation: Safety run-in results from OPTIMIZE Oral December 13
9:30 AM - 11:00 Am
Presentation: 10:45 AM
Session: 722
Antonio Jimenez-Jimenez
Pre-transplant flow cytometry in AML patients undergoing allogeneic HCT after hypomethylating agent and venetoclax therapy Oral December 13
4:30 PM - 6:00 PM
Presentation: 4:45 PM
Session: 732
Jesse Tettero
Hematopoietic cell transplantation for hepatosplenic T-cell lymphoma: A contemporary CIBMTR analysis Poster December 13
6:00 PM - 8:00 PM
Session: 625
Aung M. Tun
Outcomes of allogeneic and autologous hematopoietic cell transplantation for adult T-cell leukemia/lymphoma: A contemporary CIBMTR registry analysis Poster December 13
6:00 PM - 8:00 PM
Session: 625
Robert Stuver
Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis after reduced-intensity mismatched unrelated donor peripheral blood stem cell transplantation: 2-year outcomes from the ACCESS trial Poster December 13
6:00 PM - 8:00 PM
Session: 722
Mahasweta Gooptu
Allogeneic hematopoietic cell transplantation for mycosis fungoides and sezary syndrome: A center for international blood and marrow transplant research (CIBMTR) analysis Poster December 13
6:00 PM - 8:00 PM
Session: 732
Amrita Goyal-O'Leary
Hematopoietic progenitor cell transplantation for enteropathy-associated T-cell lymphoma (EATL) and monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL): a CIBMTR analysis Poster December 13
6:00 PM - 8:00 PM
Session: 732     
Taylor R. Brooks
Health outcomes in socially vulnerable pediatric patients after hematopoietic cell transplantation Poster December 13
6:00 PM - 8:00 PM
Session: 906
Emmanuel Aryee
Real-world outcomes of lisocabtagene maraleucel (liso-cel) for patients (pts) with second-line (2L) relapsed or refractory (R/R) large B-cell lymphoma (LBCL): 2-y follow-up from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry Poster December 13
6:00 PM - 8:00 PM
Session: 906
Bradley Hunter
MONDAY, DECEMBER 14
No evidence of clinical benefit from mycophenolate mofetil use with PTCy-CNI prophylaxis after HLA-matched donor HCT Oral December 14
4:30 PM - 6:00 PM
Presentation: 5:30 PM
Session: 722
Rima Saliba
Reduced dose post-transplantation cyclophosphamide achieves high infection-free and overall survival in mismatched unrelated donor transplantation using reduced intensity/non-myeloablative conditioning: Initial results from OPTIMIZE Oral December 14
4:30 PM - 6:00 PM
Presentation: 5:45 PM
Session: 722
Brian Shaffer
Comparing QOL trajectories of ACCESS trial, BMT CTN 1703, and real-world patients in the CIBMTR registry 1-year post-hematopoietic cell transplantation (HCT) Poster December 14
6:00 PM - 8:00 PM
Session: 908
Richard Newcomb